Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses
ASCO 2026: Lung cancer roundup
Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer
ASCO 2026: Highlights and analysis
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer
Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety
ASCO 2026: Latest in prostate cancer